Antirreabsortivos ósseos em pacientes odontológicos: noções de conduta para o cirurgião-dentista: uma revisão integrativa/ Bone antiresorptive drugs in dental patients: notions of conduct for dentists: an integrative review

Authors

  • Bruno Araujo Lauande Massete Ribeiro
  • Danielle Barros de Oliveira
  • Mayron Guedes Silva
  • Wandersson Ferreira Saraiva
  • Paulo Maria Santos Rabelo Júnior
  • Rosana Costa Casanovas

DOI:

https://doi.org/10.34119/bjhrv4n2-387

Keywords:

Osteonecrose, Osteonecrose da Arcada Ósseo Dentária Associada a Bifosfonatos, Assistência odontológica.

Abstract

Os antirreabsortivos caracterizam-se por fármacos que atuam inibindo a reabsorção óssea e, em geral, são indicados para tratamento de osteoporose, doença de Paget, prevenção de metástase decorrente de mielomas múltiplos e outros tumores. Entretanto, esses medicamentos têm como efeito colateral a Osteonecrose dos Maxilares Associada a Medicamentos, onde observa-se uma região de osso exposto na maxila ou mandíbula. Objetivou-se analisar a produção científica acerca do assunto e descrever, através de uma revisão integrativa da literatura, as noções de conduta para o cirurgião dentista diante dos efeitos adversos dos antirreabsortivos na cavidade oral. Foi realizada uma busca através das bases de dados PubMed®, MEDLINE®, LILACS® e SciELO® utilizando para a pesquisa os termos “antirreabsortivos”, “osteonecrose”, “Osteonecrose dos Maxilares Associada ao uso de Medicamentos” e “OMAM”, sendo incluídos aqueles que foram artigos publicados em um período ilimitado, em português, inglês e espanhol e disponibilizados na íntegra. Nota-se a necessidade de o cirurgião-dentista fazer um bom diagnóstico das lesões em seus diferentes estágios de desenvolvimentos, além da prevenção da osteonecrose com terapias conservadoras.

References

STARLING, Isabela Rizel Nogueira. TRATAMENTO DE OSTEONECROSE EXTENSA ASSOCIADA AO USO DE ANTI REABSORTIVOS: RELATO DE CASO E REVISÃO DE LITERATURA. Tese (Especialização em Cirurgia e Traumatologia Buco-maxilo-facial) - Faculdade de Odontologia, Universidade Federal de Minas Gerais. Belo Horizonte, p. 53. 2018.

RIBEIRO, Guilherme H.; CHRUN, Emanuely S.; DUTRA, Kamile L.; DANIEL, Filipe I.; GRANDO, Liliane J.. OSTEONECROSIS OF THE JAWS: A REVIEW AND UPDATE IN ETIOLOGY AND TREATMENT. Brazilian Journal Of Otorhinolaryngology, [S.L.], v. 84, n. 1, p. 102-108, jan. 2018a. Elsevier BV. http://dx.doi.org/10.1016/j.bjorl.2017.05.008.

JESUS, Adriele Pereira de; SOUSA FILHO, Francisnei Santos; CARDOSO, Juliana Andrade; CÂNCIO, Antônio Varela; SIMÕES, Cinthia Coelho; FARIAS, Jener Gonçalves de. TRATAMENTO CIRÚRGICO PARA OSTEONECROSE DOS MAXILARES INDUZIDA POR BISFOSFONATOS: RELATOS DE CASOS. Revista da Faculdade de Odontologia - Upf, [S.L.], v. 24, n. 1, p. 22-30, 28 mar. 2019. UPF Editora. http://dx.doi.org/10.5335/rfo.v24i1.8790.

RAMOS, Emilio Andrés; DIAMANTE, Maximiliano; MUIÑO, Juan Manuel; ANTONELLI, Ludmila; GUTIÉRREZ, Josefina; MINIGUTTI, Marcelo; OLIVERA, Brunella; LLEVARÍA, Diego; PUIA, Sebastián Ariel; GUELMAN, Rodolfo; ECHAGUE, Alejo; CARUSO, Diego. PREVENCIÓN DE OSTEONECROSIS ASOCIADA A MEDICAMENTOS Y ENSAYO CLÍNICO MULTICÉNTRICO. Rev. Fac. Odontol. (B.Aires); 34(76): 7-15, 2019

CAMINHA, Raquel D’Aquino Garcia; CHICRALA, Gabriela Moura; SOARES, Luiz Alberto Valente; SANTOS, Paulo Sérgio da Silva. RISK PROFILE FOR ANTIANGIOGENIC AGENT-RELATED OSTEONECROSIS OF THE JAWS. Einstein (São Paulo), [S.L.], v. 17, n. 3, p. 1-9, 2019. Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein. http://dx.doi.org/10.31744/einstein_journal/2019rw4628.

BARIN, Luisa Machado; PILLUSKY, Fernanda Maia; PASINI, Marcela Mozzaquatro; DANESI, Cristiane Cademartori. OSTEONECROSE DOS MAXILARES ASSOCIADA AO USO DE BIFOSFONATOS: UMA REVISÃO DE LITERATURA. Rev. Odontol. Univ. Cid. São Paulo. 28(2): 126-34,mai-ago, 2016.

Vilela-Carvalho LN, Tuany-Duarte N, Andrade-Figueiredo M, LópezOrtega k. OSTEONECROSIS DE LOS MAXILARES RELACIONADOS CON EL USO DE MEDICAMENTOS: DIAGNÓSTICO, TRATAMIENTO Y PREVENCIÓN. Rev. CES Odont. 31(2): 48-63. 2018.

GALVÃO, Letícia Gonçalves; DE MOURA, Rafaella Porto. USO DE BISFOSFONATOS E SUA RELAÇÃO COM A OSTEONECROSE DOS MAXILARES: REVISÃO DE LITERATURA. Tese (Apresentado ao Departamento de Odontologia) - Universidade de Taubaté, p. 33. 2019

CHUENGUE, Eduardo Kailan Unfried; RODRIGUES, Giovana. OSTEONECROSE DOS MAXILARES EM PACIENTES TRATADOS COM BISFOSFONATOS: UMA PATOLOGIA SECUNDÁRIA Rev. Saberes, Rolim de Moura, vol. 8, n. 2, jul./set, 2018. ISSN: 2358-0909.

LUCIANO, Daniella Mayra Azevedo; DOMINGUETE, Matheus Henrique Lopes. OSTEONECROSE DOS OSSOS MAXILARES POR USO DE BIFOSFONATO. Rev da Universidade Vale do Rio Verde | v. 16 | n. 1 | jan./jul. 2018 | p. 1

SHIBAHARA T: Antiresorptive agent-related osteonecrosis of the jaw (ARONJ): A twist of fate in the bone. Tohoku J Exp Med. 2019, 247:75-86.

Migliorati CA, Brennan MT, Peterson DE. Medication-Related Osteonecrosis of the Jaws. J Natl Cancer Inst Monogr. 2019 Aug 1;2019(53)

Richardson ED, Price DK, Figg WD. Significant addition to treatment options for bone metastasis in prostate cancer. Cancer Biol Ther. 2012;13(2):69–70.

Favia G, Tempesta A, Limongelli L, Crincoli V, Maiorano E: Medication-related osteonecrosis of the jaw: surgical or non-surgical treatment?. Oral Dis. 2018, 24:238-42.

Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O’Ryan F: American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg. 2014, 72:1938-56.

Lombard T, Neirinckx V, Rogister B, Gilon Y, Wislet S: Medication-related osteonecrosis of the jaw: new insights into molecular mechanisms and cellular therapeutic approaches. Stem Cells Int. 2016, 2016:8768162.

Khan AA, Morrison A, Kendler DL, et al.: Case-based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management from the International Task Force on ONJ. J Clin Densitom. 2017, 20:8-24

Moschetta M, Di Pietro G, Ria R, et al. Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. Eur J Cancer. 2010;46(2):420–429.

Carvalho A, Mendes RA, Carvalho DCJ. Osteonecrose da mandíbula associada a bifosfonatos intravenosos em doentes oncológicos. Acta Med Port 2008 21(5):505-10.

Silverman SL, Landesberg R. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med 2009 Feb;122(2 Suppl):S33-45.

FEDE, Olga di; PANZARELLA, Vera; MAUCERI, Rodolfo; FUSCO, Vittorio; BEDOGNI, Alberto; LOMUZIO, Lorenzo; BOARD, Sipmo Onj; CAMPISI, Giuseppina. The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: new paradigm of primary prevention. Biomed Research International, [S.L.], v. 2018, p. 1-10, 16 set. 2018.

NICOLATOU-GALITIS, Ourania; SCHIØDT, Morten; MENDES, Rui Amaral; RIPAMONTI, Carla; HOPE, Sally; DRUDGE-COATES, Lawrence; NIEPEL, Daniela; WYNGAERT, Tim van Den. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surgery, Oral Medicine, Oral Pathology And Oral Radiology, [S.L.], v. 127, n. 2, p. 117-135, fev. 2019.

Dal Prá KJ, Lemos CA, Okamoto R, Soubhia AM, Pellizzer EP. Efficacy of the C-terminal telopeptide test in predicting the development of bisphosphonate-related osteonecrosis of the jaw: a systematic review. Int J Oral Maxillofac Surg. 2017 Feb;46(2):151-156.

Marx RE, Cillo JE Jr, Ulloa. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007;65(12):2397- 410.

Kunchur R, Need A, Hughes T, Goss A. Clinical investigation of Cterminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009;67(6):1167-73.

Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O’Ryan F et al. International Task Force on Osteonecrosis of the Jaw. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 2015;30(1):3-23.

RAMAGLIA, Luca et al. Stage-specific therapeutic strategies of medication-related osteonecrosis of the jaws: a systematic review and meta-analysis of the drug suspension protocol. Clinical oral investigations, v. 22, n. 2, p. 597-615, 2018.

Scarpa LC, Leite LCM, Lacerda JCT, Arantes DCB. Osteonecrose nos ossos da maxila e mandíbula associada ao uso do bifosfonato de sódio. Rev Bras Pesqui Saude 2010 12(1):86-92.

Silva AS, Conceição TS, Veloso KMM, Cartágenes MSS. Análise de prontuários de pacientes com câncer de mama em tratamento com bisfosfonatos: fator de risco para manifestações orais e osteonecrose induzida. Rev Soc Bras Clín Méd 2013 jul-set;11(3):242-5.

Santos PSS, Gambirazi LM, Felix VB, Magalhães MHCG. Osteonecrose maxilar em pacientes portadores de doenças neoplásicas sob uso de bisfosfonatos. Rev Bras Hematol Hemoter 2008 dez;30(6):501-4.

Ferreira Junior CD, Casado PL, Barboza ESP. Osteonecrose associada aos bifosfonatos na odontologia. Rev Periodontia 2007 dez;17(24-30):4.

Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005 Dec 1;23(34):8580-7.

Gomez-Moreno G, Arribas-Fernandez MC, Fernandez-Guerrero M, Boquete-Castro A, Aguilar-Salvatierra A, Guardia J, et al. Bisphosphonate-associated osteonecrosis of the jaw 2 years after teeth extractions: a case report solved with non-invasive treatment. Eur Rev Med Pharmacol Sci 2014 18(9):1391-7.

RUGANI, P., ACHAM, S., KIRNBAUER, B., TRUSCHNEGG, A., OBERMAYER-PIETSCH, B., & Jakse, N. Stage-related treatment concept of medication-related osteonecrosis of the jaw-a case series. Clinical oral investigations, 19(6), 1329–1338. (2015).

CANO-DURÁN, Jorge A. et al. The role of Leucocyte-rich and platelet-rich fibrin (L-PRF) in the treatment of the medication-related osteonecrosis of the jaws (MRONJ). Journal of clinical and experimental dentistry, v. 9, n. 8, p. e1051, 2017.

PINTO, Nelson R. et al. Leucocyte-and platelet-rich fibrin (L-PRF) as a regenerative medicine strategy for the treatment of refractory leg ulcers: a prospective cohort study. Platelets, v. 29, n. 5, p. 468-475, 2018.

NØRHOLT, S. E.; HARTLEV, J. Surgical treatment of osteonecrosis of the jaw with the use of platelet-rich fibrin: a prospective study of 15 patients. International journal of oral and maxillofacial surgery, v. 45, n. 10, p. 1256-1260, 2016.

KIM, Jin-Woo; KIM, Sun-Jong; KIM, Myung-Rae. Leucocyte-rich and platelet-rich fibrin for the treatment of bisphosphonate-related osteonecrosis of the jaw: a prospective feasibility study. British journal of oral and maxillofacial surgery, v. 52, n. 9, p. 854-859, 2014.

MALUF, Gustavo; CALDAS, Rogério Jardim; SANTOS, Paulo Sérgio Silva. Use of leukocyte-and platelet-rich fibrin in the treatment of medication-related osteonecrosis of the jaws. Journal of Oral and Maxillofacial Surgery, v. 76, n. 1, p. 88-96, 2018.

TENORE, Gianluca et al. Management of Medication-Related Osteonecrosis of the Jaw (MRONJ) Using Leukocyte-and Platelet-Rich Fibrin (L-PRF) and Photobiomodulation: A Retrospective Study. Journal of Clinical Medicine, v. 9, n. 11, p. 3505, 2020.

MINAMISAKO, M. C. et al. Medication-related osteonecrosis of jaws: A low-level laser therapy and antimicrobial photodynamic therapy case approach. Case Rep Dent, v. 2016, 6267406, 2016. doi: 10.1155/2016/6267406.

MENEZES, I. L. et al. Photodynamic therapy in the treatment of mandibular osteonecrosis by bisphosphonates: a review. Brazilian Journal of Health Review, Curitiba, v.4, n.1, p 2652-2665 jan./feb. 2021

SOUZA, Smyrna Luiza Ximenes de et al. Photodynamic therapy as a coadjuvant in the treatment of medication-related osteonecrosis of the jaw (MRONJ) SALUSVITA, Bauru, v. 38, n. 4, p. 1093-1105, 2019.

PRAZMO, E. J.; KWASNY, M.; LAPINSKI, A. M. Photodynamic therapy as a promising method used in the treatment of oral diseases. Adv Clin Exp Med, Wroclaw, v. 25, n. 4, p. 799-807, 2016.

RIBEIRO, G. H. et al. Osteoradionecrosis of the jaws: case series treated with adjuvant low-level laser therapy and antimicrobial photodynamic therapy. J Appl Oral Sci, v. 26, p. e20170172, 2018b. doi: 10.1590/1678-7757-2017-0172.

Freiberger JJ, Padilla-Burgos R, McGraw T, et al: What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. J Oral Maxillofac Surg 70:1573, 2012.

Freiberger JJ: Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 67:96, 2009.

Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL, Migliorati CA, Khan A, Morrison A, Anderson H, Murphy BA, Alston-Johnson D, Mendes RA, Beadle BM, Jensen SB, Saunders DP. Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. J Clin Oncol. 2019 Sep 1;37(25):2270-2290.

Published

2021-04-18

Issue

Section

Original Papers